SCHEMBL4038110

SCHEMBL4038110

CC(C)(C)c1ccc(S(=O)(=O)N2CCN(C(=O)c3ccccc3)C(C(=O)NCc3ccccc3)C2)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
F2 P00734 1/20 0.50
F10 P00742 1/20 0.50
GAA P10253 2/20 0.49
CA1 P00915 2/20 0.48
CA2 P00918 2/20 0.48
CA4 P22748 2/20 0.48
CA9 Q16790 2/20 0.48
ALDH1A1 P00352 5/20 0.48
KMT2A Q03164 2/20 0.48
MEN1 O00255 1/20 0.48
FKBP1A P62942 1/20 0.47
LMNA P02545 3/20 0.47
SMN1; SMN2 Q16637 2/20 0.47
PKM P14618 2/20 0.47
GLA P06280 1/20 0.47
HTT P42858 1/20 0.47
ADAM17 P78536 1/20 0.46
USP2 O75604 1/20 0.46
RAB9A P51151 1/20 0.45
MAPT P10636 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4034634 0.88 ALDH1A1 (0.64) GAAALDH1A1KMT2AMEN1SMN1; SMN2
SCHEMBL4033088 0.76 ALDH1A1 (0.68) GAAALDH1A1KMT2AMEN1SMN1; SMN2
SCHEMBL13571106 0.73 FKBP1A (0.69) ALDH1A1KMT2AMEN1FKBP1ALMNA
SCHEMBL926836 0.73 FKBP1A (0.48) GAAALDH1A1KMT2AMEN1FKBP1A
SCHEMBL735124 0.73 LMNA (0.66) GAAALDH1A1KMT2AMEN1LMNA
SCHEMBL1380872 0.73 ALDH1A1 (0.45) GAACA1CA2CA4CA9
SCHEMBL26673510 0.72 F2 (0.48) F2F10GAACA1CA2
SCHEMBL3383937 0.72 HSD11B1 (0.61) GAAALDH1A1KMT2AMEN1FKBP1A
SCHEMBL26673488 0.72 ALDH1A1 (0.53) F2F10GAAALDH1A1KMT2A
SCHEMBL26673600 0.71 PKM (0.49) F2F10GAAALDH1A1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1592389-B1 PIPERAZINE-2-CARBOXAMIDE DERIVATIVES SERONO LAB (CH) 2009-04-22 EP claimed
US-20070142391-A1 Piperazine-2-carboxamide derivatives MERCK SERONO SA (CH) 2007-06-21 US claimed
EP-1592389-A2 PIPERAZINE-2-CARBOXAMIDE DERIVATIVES Applied Research Systems ARS Holding N.V. (AN) 2005-11-09 EP claimed
WO-2004071390-A2 PIPERAZINE-2-CARBOXAMIDE DERIVATIVES APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) 2004-08-26 WO claimed
US-8404690-B2 Piperazine-2-carboxamide derivatives MERCK SERONO SA (CH) 2013-03-26 US disclosed
EP-1592389-B1 PIPERAZINE-2-CARBOXAMIDE DERIVATIVES SERONO LAB (CH) 2009-04-22 EP disclosed
US-20070142391-A1 Piperazine-2-carboxamide derivatives MERCK SERONO SA (CH) 2007-06-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070142391-A1 Piperazine-2-carboxamide derivatives P2RX5, P2RX2, NPY5R F2 726/4885F10 713/4885GAA 4649/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.